Clene Inc.
CLNN
查看详细走势图
4.290USD
+0.370+9.44%
收盘 02/06, 16:00（美东）报价延迟15分钟
43.84M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+9.44%
5天
+4.89%
1月
-31.69%
6月
+16.89%
今年开始到现在
-26.92%
1年
-1.72%
查看详细走势图
TradingKey Clene Inc.股票评分
单位: USD 更新时间: 2026-02-06操作建议
Clene Inc.当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名171/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价31.86。中期看，股价处于下降通道。近一个月，市场表现非常差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Clene Inc.评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Clene Inc.亮点
亮点风险
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
业绩增长期
公司处于发展阶段，最新年度总收入342.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入342.00K美元
估值合理
公司最新PE估值-1.25，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值222.91K
分析师目标
根据
7
位分析师
买入
评级
31.857
目标均价
+698.42%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Clene Inc.新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Clene Inc.简介
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.
公司代码CLNN
公司Clene Inc.
CEOEtherington (Robert)
网址https://clene.com/
相关品种
